Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/67961 |
Resumo: | Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint synovial inflammation, as well as cartilage and bone tissue destruction. Current strategies for the treatment of RA can reduce joint inflammation, but the treatment options still represent stability concerns since they are not sufficient and present a fast clearing. Thus, several drug delivery systems (DDS) have been advanced to tackle this limitation. Injectable gellan gum (GG) hydrogels, reduced by physical crosslinking methods, also being proposed as DDS, but this kind of crosslinking can produce hydrogels that become weaker in physiological conditions. Nevertheless, enzymatic crosslinking emerged as an alternative to increase mechanical strength, which can be adjusted by the degree of enzymatic crosslinking. In this study, tyramine-modified gellan gum (Ty-GG) hydrogels were developed via horseradish peroxidase (HRP) crosslinking; and betamethasone was encapsulated within, to increase the specificity and safety in the treatment of patients with RA. Physicochemical results showed that it was possible to modify GG with tyramine, with a degree of substitution of approximately 30%. They showed high mechanical strength and resistance, presenting a controlled betamethasone release profile over time. Ty-GG hydrogels also exhibited no cytotoxic effects and do not negatively affected the metabolic activity and proliferation of chondrogenic primary cells. Furthermore, the main goal was achieved since betamethasone-loaded Ty-GG hydrogels demonstrated to have a more effective therapeutic effect when compared with the administration of betamethasone alone. Therefore, the developed Ty-GG hydrogels represent a promising DDS and a reliable alternative to traditional treatments in patients with RA |
id |
RCAP_e6bb54a0fa869d97642399dbca020e92 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/67961 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatmentDrug deliveryHorseradish peroxidaseHyperplasic synoviumRheumatoid arthritiTy-GG hydrogelsRheumatoid arthritisCiências Médicas::Biotecnologia MédicaScience & TechnologyRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint synovial inflammation, as well as cartilage and bone tissue destruction. Current strategies for the treatment of RA can reduce joint inflammation, but the treatment options still represent stability concerns since they are not sufficient and present a fast clearing. Thus, several drug delivery systems (DDS) have been advanced to tackle this limitation. Injectable gellan gum (GG) hydrogels, reduced by physical crosslinking methods, also being proposed as DDS, but this kind of crosslinking can produce hydrogels that become weaker in physiological conditions. Nevertheless, enzymatic crosslinking emerged as an alternative to increase mechanical strength, which can be adjusted by the degree of enzymatic crosslinking. In this study, tyramine-modified gellan gum (Ty-GG) hydrogels were developed via horseradish peroxidase (HRP) crosslinking; and betamethasone was encapsulated within, to increase the specificity and safety in the treatment of patients with RA. Physicochemical results showed that it was possible to modify GG with tyramine, with a degree of substitution of approximately 30%. They showed high mechanical strength and resistance, presenting a controlled betamethasone release profile over time. Ty-GG hydrogels also exhibited no cytotoxic effects and do not negatively affected the metabolic activity and proliferation of chondrogenic primary cells. Furthermore, the main goal was achieved since betamethasone-loaded Ty-GG hydrogels demonstrated to have a more effective therapeutic effect when compared with the administration of betamethasone alone. Therefore, the developed Ty-GG hydrogels represent a promising DDS and a reliable alternative to traditional treatments in patients with RANorte2020 project (“NORTE-08-5369-FSE-000044”), REMIX project (G.A. 778078 — REMIX — H2020-MSCA-RISE-2017), and Gilson Lab, Chonbuk National University, Republic of Korea. The FCT distinction attributed to J. Miguel Oliveira under the Investigator FCT program (IF/01285/2015) is also greatly acknowledged. C. Gonçalves also wish to acknowledge FCT for supporting her research (No. SFRH/BPD/94277/2013)SpringerUniversidade do MinhoOliveira, Isabel Maria Lopes MatosGonçalves, C.Shin, M. E.Lee, S.Reis, R. L.Khang, G.Oliveira, J. M.20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/67961engOliveira I. M., Gonçalves C., Shin M. E., Lee S., Reis R. L., Khang G., Oliveira J. M. Enzymatically crosslinked Tyramine-Gellan Gum Hydrogels as Drug Delivery System for Rheumatoid Arthritis Treatment, Drug Delivery and Translational Research, doi:10.1007/s13346-020-00855-9, 2021.2190-393X2190-394810.1007/s13346-020-00855-932924098https://link.springer.com/article/10.1007/s13346-020-00855-9#Ack1info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:52:53Zoai:repositorium.sdum.uminho.pt:1822/67961Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:52:07.442045Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
title |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
spellingShingle |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment Oliveira, Isabel Maria Lopes Matos Drug delivery Horseradish peroxidase Hyperplasic synovium Rheumatoid arthriti Ty-GG hydrogels Rheumatoid arthritis Ciências Médicas::Biotecnologia Médica Science & Technology |
title_short |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
title_full |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
title_fullStr |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
title_full_unstemmed |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
title_sort |
Enzymatically crosslinked Tyramine-Gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment |
author |
Oliveira, Isabel Maria Lopes Matos |
author_facet |
Oliveira, Isabel Maria Lopes Matos Gonçalves, C. Shin, M. E. Lee, S. Reis, R. L. Khang, G. Oliveira, J. M. |
author_role |
author |
author2 |
Gonçalves, C. Shin, M. E. Lee, S. Reis, R. L. Khang, G. Oliveira, J. M. |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Oliveira, Isabel Maria Lopes Matos Gonçalves, C. Shin, M. E. Lee, S. Reis, R. L. Khang, G. Oliveira, J. M. |
dc.subject.por.fl_str_mv |
Drug delivery Horseradish peroxidase Hyperplasic synovium Rheumatoid arthriti Ty-GG hydrogels Rheumatoid arthritis Ciências Médicas::Biotecnologia Médica Science & Technology |
topic |
Drug delivery Horseradish peroxidase Hyperplasic synovium Rheumatoid arthriti Ty-GG hydrogels Rheumatoid arthritis Ciências Médicas::Biotecnologia Médica Science & Technology |
description |
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint synovial inflammation, as well as cartilage and bone tissue destruction. Current strategies for the treatment of RA can reduce joint inflammation, but the treatment options still represent stability concerns since they are not sufficient and present a fast clearing. Thus, several drug delivery systems (DDS) have been advanced to tackle this limitation. Injectable gellan gum (GG) hydrogels, reduced by physical crosslinking methods, also being proposed as DDS, but this kind of crosslinking can produce hydrogels that become weaker in physiological conditions. Nevertheless, enzymatic crosslinking emerged as an alternative to increase mechanical strength, which can be adjusted by the degree of enzymatic crosslinking. In this study, tyramine-modified gellan gum (Ty-GG) hydrogels were developed via horseradish peroxidase (HRP) crosslinking; and betamethasone was encapsulated within, to increase the specificity and safety in the treatment of patients with RA. Physicochemical results showed that it was possible to modify GG with tyramine, with a degree of substitution of approximately 30%. They showed high mechanical strength and resistance, presenting a controlled betamethasone release profile over time. Ty-GG hydrogels also exhibited no cytotoxic effects and do not negatively affected the metabolic activity and proliferation of chondrogenic primary cells. Furthermore, the main goal was achieved since betamethasone-loaded Ty-GG hydrogels demonstrated to have a more effective therapeutic effect when compared with the administration of betamethasone alone. Therefore, the developed Ty-GG hydrogels represent a promising DDS and a reliable alternative to traditional treatments in patients with RA |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 2021-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/67961 |
url |
http://hdl.handle.net/1822/67961 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Oliveira I. M., Gonçalves C., Shin M. E., Lee S., Reis R. L., Khang G., Oliveira J. M. Enzymatically crosslinked Tyramine-Gellan Gum Hydrogels as Drug Delivery System for Rheumatoid Arthritis Treatment, Drug Delivery and Translational Research, doi:10.1007/s13346-020-00855-9, 2021. 2190-393X 2190-3948 10.1007/s13346-020-00855-9 32924098 https://link.springer.com/article/10.1007/s13346-020-00855-9#Ack1 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Springer |
publisher.none.fl_str_mv |
Springer |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133112110678016 |